Sökning: id:"swepub:oai:DiVA.org:umu-88318" >
A prediction of the...
A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers
-
Smink, P. A. (författare)
-
Hoekman, J. (författare)
-
Grobbee, D. E. (författare)
-
visa fler...
-
Eijkemans, M. J. C. (författare)
-
Parving, H-H (författare)
-
Persson, F. (författare)
-
Ibsen, H. (författare)
-
- Lindholm, Lars H. (författare)
- Umeå universitet,Allmänmedicin
-
Wachtell, K. (författare)
-
de Zeeuw, D. (författare)
-
Heerspink, H. J. Lambers (författare)
-
visa färre...
-
(creator_code:org_t)
- 2013-03-06
- 2014
- Engelska.
-
Ingår i: European Journal of Preventive Cardiology. - : Oxford University Press (OUP). - 2047-4873 .- 2047-4881. ; 21:4, s. 434-441
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Introduction We recently developed and validated in existing trials a novel algorithm (PRE score) to predict long-term drug efficacy based on short-term (month-6) drug-induced changes in multiple risk markers. To show the value of the PRE score for ongoing and planned clinical trials, we here report the predicted long-term cardio-renal efficacy of aliskiren in type 2 diabetes, which was investigated in the ALTITUDE trial, but unknown at the time this study was conducted. Methods We established the relation between multiple risk markers and cardio-renal endpoints (as defined in ALTITUDE) using a background database from past clinical trials. The short-term effect of aliskiren on multiple risk markers was taken from the AVOID trial. A PRE score was developed by multivariate Cox analysis in the background population and was then applied to the baseline and month-6 measurements of the aliskiren treatment arm of the AVOID trial to predict cardio-renal risk. The net risk difference at these time-points, after correction for placebo effects, was taken to indicate the estimated long-term cardio-renal risk change. Results Based on the PRE score, we predicted that aliskiren treatment in ALTITUDE would confer a relative risk change of -7.9% (95% CI -2.5 to -13.4) for the cardio-renal endpoint, a risk change of -5.1% (-1.2 to -9.0) for the CV endpoint and a non-significant risk change of -19.9% (-42.1 to +2.1) for the renal endpoint. Conclusions PRE score estimations suggested that aliskiren has only a marginal additive protective effect on cardio-renal endpoints. These predictions were validated by the results of the ALTITUDE trial, confirming the potential of the PRE score to prospectively predict drug efficacy on cardio-renal outcomes.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- direct renin inhibition
- biomarkers
- Type 2 diabetes
- nephropathy
- cardiovascular disease
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Smink, P. A.
-
Hoekman, J.
-
Grobbee, D. E.
-
Eijkemans, M. J. ...
-
Parving, H-H
-
Persson, F.
-
visa fler...
-
Ibsen, H.
-
Lindholm, Lars H ...
-
Wachtell, K.
-
de Zeeuw, D.
-
Heerspink, H. J. ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Umeå universitet